Portal hypertension
ICD-10 K76.6 · ICD-11 DB98.7

What to Do for Portal Hypertension When First-Line Therapy Fails to Control Refractory Ascites in Cirrhosis

In patients with liver cirrhosis, ascites that does not respond to intensive diuretic therapy is a clinically defined condition requiring a structured next-step approach. When established first-line interventions have not achieved control of ascites or improvement in renal function, a specific protocol guides management.

Clinical Scenario — Cirrhosis with Diuretic-Resistant Ascites

This protocol targets patients with cirrhosis whose ascites meets the definition of diuretic resistance: a mean weight loss of less than 0.8 kg over 4 days and urinary sodium below sodium intake, despite intensive diuretic therapy sustained for at least one week.

First-Line Therapy That Did Not Achieve Its Goals

This protocol applies after large-volume paracentesis with albumin, vasoconstrictor therapy (midodrine or terlipressin), rifaximin, and tolvaptan have been used and have failed to achieve control of ascites and improvement in renal function.

Next-Step Approach

In carefully selected patients with cirrhosis, a shunt-based interventional procedure may prolong transplant-free survival and offers an alternative to repeated large-volume paracentesis. Eligibility is determined by specific clinical and biochemical criteria. The complete candidacy criteria and structured regimen are available in the full protocol.

References

DOI: 10.1016/j.jceh.2022.03.002

A mean weight loss of <0.8 kg over 4 days and urinary sodium less than sodium intake in a patient with cirrhosis on intensive diuretic therapy (furosemide 160 mg/day and spironolactone 400 mg/day) for at least one week is termed as diuretic resistant ascites.

TIPS in carefully selected patients can prolong the transplant-free survival and may be preferred over repeated large volume paracentesis.

Polytetrafluoroethylene covered stents have patency rates of 90% at two years and are preferred over bare-metal stents.

Age <70 years, serum bilirubin <3 mg/dl and MELD score <18 with no history of hepatic encephalopathy are excellent candidates for TIPS.

View source ↗